Perspectives of Subcutaneous Velcade at Home of Patients With Myeloma.

NCT05163405 | Completed DMC FDA Drug

• 1 other identifier: Velcade at home
• Study Type: observational
• Target: 10
• Locations: 1 country
• Sites: 1

Brief Summary

In the present study, we have trained 10 patients in subcutaneous self-administration of Velcade. After their training, patients will alternately receive their treatment in the hospital and at home by self-administration. In keeping with common practice, a nurse contacts the patients by telephone before 9.00 am on the day of treatment to ensure that the patient is physically "fit" to receive the medication and to discuss any side effects. To highlight the advantages and disadvantages of the changed treatment practice from the perspectives of both patients and healthcare professionals, data is collected from two consecutive semi-structured interviews with n = 10 patients and n = 1 focus group interview of the healthcare professionals involved. Moreover, time registration of medication administration both at the hospital and in the patients' home is done. The qualitative data will be analyzed via the method of condensation and continual quantitative data will form the basis of a cost-benefit analysis.

Conditions

Multiple Myeloma

Outcome Measures

Primary Outcomes (1)

• Patients experience of self-administration of Velcade

  Qualitative interviews with all 10 included patients

  Through study completion, from 01. dec. 2019 until 01. jun. 2022

Secondary Outcomes (3)

• Organizational perspective

  Through study completion, from 01. dec. 2019 until 01. jun. 2022

• Health care perspective

  Through study completion, from 01. dec. 2019 until 01. jun. 2022

• Financial perspective

  Through study completion, from 01. dec. 2019 until 01. jun. 2022

Interventions

Bortezomib DRUG

Self-administration of subcutaneously Velcade.

Also known as: Velcade

Eligibility Criteria

• Sex: all
• Healthy Volunteers: No
• Age Groups: Child (0-17), Adult (18-64), Older Adult (65+)
• Sampling Method: Non-Probability Sample

Study Population

Patients with Multiple Myeloma in treatment with Velcade in Department of Hematology X, outpatient clinic, at Odense University Hospital.

You may qualify if:

• Patients must have Multiple Myeloma
• Patients (or their relatives) must be deemed physically and cognitively suitable and willing for self-administration of subcutaneous Velcade
• Patients must be able to understand and speak Danish
• Patients must have received a minimum of 1 treatment cycle in the outpatient clinic

You may not qualify if:

• Lack of willingness to participate in scheduled interviews
• Patients who are cognitively affected
• Must not be receiving trial treatment

Sponsors & Collaborators

• Karin B. Ø. Dieperink: lead

Study Sites (1)

Odense University Hospital

Odense, 5000, Denmark

Location

MeSH Terms

Conditions

Multiple Myeloma

Interventions

Bortezomib

Condition Hierarchy (Ancestors)

Neoplasms, Plasma Cell; Neoplasms by Histologic Type; Neoplasms; Hemostatic Disorders; Vascular Diseases; Cardiovascular Diseases; Paraproteinemias; Blood Protein Disorders; Hematologic Diseases; Hemic and Lymphatic Diseases; Hemorrhagic Disorders; Lymphoproliferative Disorders; Immunoproliferative Disorders; Immune System Diseases

Intervention Hierarchy (Ancestors)

Boronic Acids; Acids, Noncarboxylic; Acids; Inorganic Chemicals; Boron Compounds; Organic Chemicals; Pyrazines; Heterocyclic Compounds, 1-Ring; Heterocyclic Compounds

Study Officials

• Karin Brochstedt Dieperink, RN

  Odense University Hospital. Department of Oncology.

  STUDY DIRECTOR

Study Design

• Study Type: observational
• Observational Model: OTHER
• Time Perspective: PROSPECTIVE
• Sponsor Type: OTHER
• Responsible Party: SPONSOR INVESTIGATOR
• PI Title: Nurse, PhD, Associate Professor

Study Record Dates

• First Submitted: December 3, 2021
• First Posted: December 20, 2021
• Study Start: December 1, 2019
• Primary Completion: January 1, 2022
• Study Completion: June 1, 2022
• Last Updated: August 22, 2025

Record last verified: 2025-08

Data Sharing

• IPD Sharing: Will not share

Locations

DK (1)